<DOC>
	<DOCNO>NCT03080051</DOCNO>
	<brief_summary>The overall goal image trial evaluate [ 18F ] MNI-952 ( also know [ 18F ] UCB-K ) , tau target PET radioligand .</brief_summary>
	<brief_title>Evaluation 18FMNI-952 Potential PET Radioligand Imaging Tau Protein Brain</brief_title>
	<detailed_description>The overall goal image trial evaluate [ 18F ] MNI-952 ( also know [ 18F ] UCB-K ) , tau target PET radioligand . - To characterize [ 18F ] MNI-952 , PET radioligand image tau . - To visually quantitatively assess brain uptake pharmacokinetics [ 18F ] MNI-952 , PET image marker tau pathology individual Progressive Supranuclear Palsy ( PSP ) Alzheimer 's disease ( AD ) compare healthy volunteer ( HV ) . - To evaluate safety single injection [ 18F ] MNI-952 . - To compare distribution tau ( use [ 18F ] MNI-952 ) Aâ ( use florbetapir ) AD subject .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Female subject must document medical record physician 's note either surgically sterile ( mean hysterectomy , bilateral oophorectomy , tubal ligation ) postmenopausal least 1 year , childbearing potential , must commit use barrier contraception method duration study . Male subject partner childbearing potential must commit use two method contraception , one barrier method male subject study duration . Male subject must donate sperm study duration 90 day follow participation . Willing able cooperate study procedure Inclusion Criteria healthy volunteer subject : Males female age &lt; 55 year . Healthy clinically relevant find physical examination screen upon report [ 18F ] MNI952 image visit . No neurologic impairment judge investigator No family history Alzheimer 's disease neurological disease associate dementia Have CDR score=0 Inclusion Criteria subject diagnosis probable Alzheimer 's disease ( AD ) : Males female age 50 90 year . Have probable Alzheimer 's disease , base NINCDS/ADRDA DSMIV criterion . Have CDR score 0.5 great screening . Have MMSE score ≤ 28 . Have screen [ 18F ] florbetapir PET image demonstrate amyloid binding base qualitative ( visual read ) A brain MRI support diagnosis AD , evidence focal disease account dementia MRI exclusion criterion . Medications take symptomatic treatment AD must maintain stable dosage regimen least 30 day screen visit The subject appropriate caregiver capable accompany subject , necessary . Signed date write informed consent obtain subject and/or subject 's legally authorize representative caregiver ( applicable ) . Inclusion Criteria subject diagnosis probable Progressive Supranuclear Palsy ( PSP ) : Males female age 50 90 year . Has clinical diagnosis PSP base NINDS Society PSP criterion ( Litvan , et al 1996 ) . Have screen DaTSCAN SPECT image demonstrate evidence dopamine transporter deficit base qualitative ( visual ) read . A brain MRI support diagnosis PSP , evidence focal disease MRI exclusion criterion . Medications take symptomatic treatment PSP must maintain stable dosage regimen least 30 day screen visit . The subject appropriate caregiver capable accompany subject , necessary . Signed date write informed consent obtain subject subject 's legally authorize representative caregiver ( applicable ) . Current prior history alcohol drug abuse . Laboratory test clinically significant abnormality and/or clinically significant unstable medical illness . Subject receive investigational drug device within 30 day screen Prior participation research protocols clinical care last year radiation exposure exceed effective dose 50 mSv , would acceptable annual limit establish US Federal Guidelines . Pregnancy , lactate breastfeeding . Evidence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , neoplastic , endocrine , alternative neurological , immunodeficiency , pulmonary , disorder disease . Unsuitable vein repeat venipuncture . MRI exclusion criterion include : Findings cerebrovascular disease ( two lacunar infarct , territorial infarct &gt; 1cm3 , deep white matter abnormality correspond overall Fazekas scale 3 least one confluent hyperintense lesion FLAIR sequence ≥20 mm dimension ) , infectious disease , spaceoccupying lesion , normal pressure hydrocephalus abnormality associate CNS disease . Implants implanted cardiac pacemaker defibrillator , insulin pump , cochlear implant , metallic ocular foreign body , implanted neural stimulators , CNS aneurysm clip medical implant certify MRI , history claustrophobia MRI . Exclusion criterion subject AD : Has receive treatment target amyloidβ tau within last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PSP</keyword>
	<keyword>AD</keyword>
	<keyword>HV</keyword>
</DOC>